Phosphatidylserine receptor-targeting therapies for the treatment of cancer.

Phosphatidylserine receptor-targeting therapies for the treatment of cancer.
Arch Pharm Res. 2019 Jun 06;:
Authors: Park M, Kang KW
Abstract
Asymmetric distribution of phospholipids across the plasma membrane is a unique characteristic of eukaryotic cells. Phosphatidylcholine and sphingomyelin are exposed in the outer leaflet, and phosphatidylserine (PS) is predominantly located in the inner leaflet. Redistribution of PS to the cell surface can be observed in several physiological conditions, such as apoptosis and platelet activation, or in pathological conditions, such as the release of microvesicles/exosomes from tumor tissues. PS binding to the phosphatidylserine receptor (PSR) on immune cells initiates immunosuppressive pathways that can lead to immune evasion by cancer cells. Conversely, PSR activation of cancer cells plays an important role in their survival, proliferation and metastasis. Herein, we briefly summarize both recent advances in our understanding of the pathological roles of PS and its receptor in cancer biology, as well as relevant pharmacological approaches.
PMID: 31172440 [PubMed - as supplied by publisher]

Source: Archives of Pharmacal Research - June 5, 2019 Category: Drugs & Pharmacology Authors: Park M, Kang KW Tags: Arch Pharm Res Source Type: research